BioStem’s Amnion Chorion Allograft: Superior Outcomes Proven in Clinical Study
BioStem Technologies, a leading regenerative medicine company based in Poomano Beach, Florida, recently announced the results of a clinical study comparing their proprietary amnion chorion allograft with the standard of care. The study, which was conducted at multiple sites, aimed to demonstrate the superior outcomes of BioStem’s allograft, further validating its clinical efficacy and supporting the company’s market expansion.
Background:
Amnion chorion allografts are tissue grafts derived from the amnion and chorion layers of the placenta. They are used in various medical applications, including wound healing and surgical procedures, due to their anti-inflammatory, antimicrobial, and angiogenic properties. BioStem’s allograft is processed using the company’s proprietary methods to preserve these beneficial properties.
Study Design:
The randomized, controlled clinical trial involved 100 patients who required surgical debridement for chronic wounds. The patients were randomly assigned to receive either BioStem’s amnion chorion allograft or the standard of care, which consisted of traditional wound dressings. The primary endpoints were wound closure rate and time to complete wound closure.
Study Results:
The study results showed that the BioStem allograft group had a significantly higher wound closure rate and a shorter time to complete wound closure compared to the standard of care group. The allograft group also had a lower rate of wound infection and required fewer surgical debridements.
Impact on Patients:
For patients, the use of BioStem’s amnion chorion allograft can lead to faster wound healing, reduced risk of infection, and fewer surgical interventions. This can result in improved quality of life, reduced healthcare costs, and shorter hospital stays.
Impact on the World:
The widespread adoption of BioStem’s amnion chorion allograft can have a significant impact on healthcare systems and patients worldwide. Faster wound healing can lead to reduced healthcare costs, as patients will require fewer hospital visits and fewer days in the hospital. Additionally, the reduced risk of infection can lead to improved patient outcomes and reduced morbidity.
Conclusion:
The clinical study conducted by BioStem Technologies further validates the clinical efficacy of their proprietary amnion chorion allograft. The allograft’s superior wound healing properties, as demonstrated by the study, can lead to improved patient outcomes, reduced healthcare costs, and shorter hospital stays. As the use of regenerative medicine continues to grow, BioStem’s allograft is poised to make a significant impact on healthcare systems and patients worldwide.
- BioStem Technologies announces clinical study results demonstrating superior outcomes of their proprietary amnion chorion allograft
- Randomized, controlled trial involved 100 patients with chronic wounds
- Primary endpoints were wound closure rate and time to complete wound closure
- BioStem allograft group had significantly higher wound closure rate and shorter time to complete wound closure
- Lower rate of wound infection and fewer surgical debridements in allograft group
- Faster wound healing can lead to reduced healthcare costs and shorter hospital stays
- Reduced risk of infection can lead to improved patient outcomes and reduced morbidity
- BioStem’s allograft poised to make a significant impact on healthcare systems and patients worldwide
